O	0	6	Effect
O	7	9	of
B-intervention	10	21	progressive
I-intervention	22	32	resistance
I-intervention	33	41	training
O	42	44	on
O	45	51	health
O	51	52	-
O	52	59	related
O	60	67	quality
O	68	70	of
O	71	75	life
O	76	78	in
O	79	82	the
O	83	88	first
O	89	93	year
O	94	99	after
O	100	106	breast
O	107	113	cancer
O	114	121	surgery
O	122	123	-
O	124	131	results
O	132	136	from
O	137	138	a
O	139	149	randomized
O	150	160	controlled
O	161	166	trial
O	166	167	.

O	168	172	Aims
O	172	173	:
O	174	176	To
O	177	184	examine
O	185	188	the
O	189	195	effect
O	196	198	of
O	199	210	progressive
O	211	221	resistance
O	222	230	training
O	231	232	(
O	232	235	PRT
O	235	236	)
O	237	239	on
O	240	246	health
O	247	254	related
O	255	262	quality
O	263	265	of
O	266	270	life
O	271	274	and
O	275	276	a
O	277	287	predefined
O	288	295	symptom
O	296	303	cluster
O	304	306	of
O	307	311	pain
O	311	312	-
O	312	317	sleep
O	317	318	-
O	318	325	fatigue
O	325	326	.

O	327	334	Methods
O	334	335	:
O	336	340	This
O	341	346	study
O	347	350	was
O	351	352	a
O	353	360	planned
O	361	370	secondary
O	371	379	analysis
O	380	382	of
O	383	384	a
O	385	395	randomized
O	396	406	controlled
O	407	412	trial
O	413	422	examining
O	423	426	the
O	427	433	effect
O	434	436	of
O	437	440	PRT
O	441	443	on
O	444	454	prevention
O	455	457	of
O	458	461	arm
O	462	472	lymphedema
O	473	475	in
O	476	477	a
O	478	488	population
O	489	491	of
O	492	497	women
O	498	505	between
B-age	506	508	18
I-age	509	512	and
I-age	513	515	75
I-age	516	521	years
B-eligibility	522	532	undergoing
I-eligibility	533	539	breast
I-eligibility	540	546	cancer
I-eligibility	547	554	surgery
I-eligibility	555	559	with
I-eligibility	560	568	axillary
I-eligibility	569	574	lymph
I-eligibility	575	579	node
I-eligibility	580	590	dissection
O	590	591	.

O	592	604	Participants
O	605	609	were
O	610	619	allocated
O	620	622	by
O	623	631	computer
O	632	645	randomization
O	646	648	to
B-control	649	654	usual
I-control	655	659	care
I-control	660	667	control
O	668	670	or
O	671	672	a
O	673	676	PRT
O	677	689	intervention
O	690	692	in
O	693	694	a
O	695	696	1
O	696	697	:
O	697	698	1
O	699	704	ratio
O	704	705	.

O	706	709	The
O	710	722	intervention
O	722	723	,
O	724	733	initiated
O	734	736	in
O	737	740	the
O	741	746	third
O	747	751	post
O	751	752	-
O	752	761	operative
O	762	766	week
O	766	767	,
O	768	777	consisted
O	778	780	of
O	781	786	three
O	787	792	times
O	793	796	PRT
O	797	800	per
O	801	805	week
O	805	806	,
O	807	817	supervised
O	818	820	in
O	821	827	groups
O	828	830	in
O	831	834	the
O	835	840	first
O	841	843	20
O	844	849	weeks
O	849	850	,
O	851	854	and
O	855	859	self
O	859	860	-
O	860	872	administered
O	873	875	in
O	876	879	the
O	880	889	following
O	890	892	30
O	893	898	weeks
O	898	899	.

O	900	913	Questionnaire
O	914	925	assessments
O	926	930	were
O	931	935	made
O	936	938	at
O	939	947	baseline
O	947	948	,
O	949	951	20
O	952	957	weeks
O	958	961	and
O	962	964	12
O	965	971	months
O	971	972	,
O	973	977	with
O	978	981	the
O	982	990	European
O	991	1003	Organization
O	1004	1007	for
O	1008	1016	Research
O	1017	1020	and
O	1021	1030	Treatment
O	1031	1033	in
O	1034	1040	Cancer
O	1041	1045	Core
O	1046	1059	questionnaire
O	1060	1061	(
O	1061	1066	EORTC
O	1067	1070	QLQ
O	1071	1074	C30
O	1074	1075	)
O	1076	1079	and
O	1080	1083	the
O	1084	1094	Functional
O	1095	1105	Assessment
O	1106	1108	of
O	1109	1116	Chronic
O	1117	1124	Illness
O	1125	1132	Therapy
O	1132	1133	-
O	1133	1134	(
O	1134	1139	FACIT
O	1139	1140	)
O	1141	1148	fatigue
O	1149	1162	questionnaire
O	1162	1163	.

O	1164	1167	The
O	1168	1175	symptom
O	1176	1183	cluster
O	1184	1186	of
O	1187	1191	pain
O	1191	1192	-
O	1192	1197	sleep
O	1197	1198	-
O	1198	1205	fatigue
O	1206	1209	was
O	1210	1218	measured
O	1219	1223	with
O	1224	1225	a
O	1226	1237	constructed
O	1238	1243	score
O	1244	1250	adding
O	1251	1256	EORTC
O	1257	1260	C30
O	1261	1270	subscales
O	1271	1273	of
O	1274	1282	insomnia
O	1282	1283	,
O	1284	1288	pain
O	1288	1289	,
O	1290	1293	and
O	1294	1301	fatigue
O	1301	1302	.

O	1303	1307	Data
O	1308	1312	were
O	1313	1320	treated
O	1321	1323	as
O	1324	1332	repeated
O	1333	1345	measurements
O	1346	1349	and
O	1350	1358	analyzed
O	1359	1363	with
O	1364	1369	mixed
O	1370	1376	models
O	1376	1377	.

O	1378	1385	Results
O	1385	1386	:
O	1387	1392	Among
B-total-participants	1393	1396	158
O	1397	1406	recruited
O	1407	1419	participants
O	1419	1420	,
O	1421	1423	we
O	1424	1429	found
O	1430	1431	a
O	1432	1442	clinically
O	1443	1451	relevant
B-outcome	1452	1461	increased
I-outcome	1462	1471	emotional
I-outcome	1472	1483	functioning
O	1484	1488	with
O	1489	1493	nine
O	1494	1500	points
B-outcome	1501	1503	at
I-outcome	1504	1508	both
I-outcome	1509	1515	follow
I-outcome	1515	1516	-
I-outcome	1516	1519	ups
O	1520	1521	(
O	1521	1522	p
O	1523	1524	=
O	1525	1526	.
O	1526	1528	02
O	1528	1529	)
O	1529	1530	,
B-outcome	1531	1534	and
I-outcome	1535	1537	16
I-outcome	1538	1541	and
I-outcome	1542	1544	11
I-outcome	1545	1551	points
I-outcome	1552	1554	at
I-outcome	1555	1557	20
I-outcome	1558	1563	weeks
I-outcome	1564	1567	and
I-outcome	1568	1570	12
I-outcome	1571	1577	months
O	1578	1590	respectively
O	1591	1592	(
O	1592	1593	p
O	1594	1595	=
O	1596	1597	.
O	1597	1599	04
O	1599	1600	)
O	1601	1603	in
O	1604	1610	social
O	1611	1622	functioning
O	1622	1623	.

O	1624	1635	Furthermore
O	1635	1636	,
O	1637	1639	in
O	1640	1643	the
O	1644	1652	subgroup
O	1653	1655	of
O	1656	1661	women
O	1662	1666	with
O	1667	1670	the
O	1671	1678	symptom
O	1679	1686	cluster
O	1687	1691	pain
O	1691	1692	-
O	1692	1697	sleep
O	1697	1698	-
O	1698	1705	fatigue
O	1706	1713	present
O	1714	1716	at
O	1717	1725	baseline
O	1725	1726	,
O	1727	1728	a
O	1729	1740	significant
O	1741	1747	effect
O	1748	1751	was
O	1752	1757	found
O	1758	1761	for
B-outcome	1762	1768	global
I-outcome	1769	1775	health
I-outcome	1776	1782	status
O	1783	1784	(
O	1784	1785	p
O	1786	1787	=
O	1788	1789	.
O	1789	1791	01
O	1791	1792	)
O	1793	1796	and
B-outcome	1797	1803	social
I-outcome	1804	1815	functioning
O	1816	1817	(
O	1817	1818	p
O	1819	1820	=
O	1821	1822	.
O	1822	1824	02
O	1824	1825	)
O	1825	1826	.

O	1827	1837	Conclusion
O	1837	1838	:
O	1839	1841	To
O	1842	1845	our
O	1846	1855	knowledge
O	1855	1856	,
O	1857	1861	this
O	1862	1864	is
O	1865	1868	the
O	1869	1874	first
O	1875	1880	study
O	1881	1883	to
O	1884	1890	report
O	1891	1901	clinically
O	1902	1910	relevant
O	1911	1918	effects
O	1919	1921	of
O	1922	1925	PRT
O	1926	1928	on
O	1929	1935	social
O	1936	1939	and
O	1940	1949	emotional
O	1950	1961	functioning
O	1962	1964	in
O	1965	1968	the
O	1969	1974	first
O	1975	1988	postoperative
O	1989	1993	year
O	1994	1999	after
O	2000	2006	breast
O	2007	2013	cancer
O	2014	2021	surgery
O	2021	2022	.

O	2023	2034	Furthermore
O	2034	2035	,
O	2036	2037	a
O	2038	2046	subgroup
O	2047	2049	of
O	2050	2055	women
O	2056	2060	with
O	2061	2064	the
O	2065	2069	pain
O	2069	2070	-
O	2070	2075	sleep
O	2075	2076	-
O	2076	2083	fatigue
O	2084	2091	symptom
O	2092	2099	cluster
O	2100	2103	had
O	2104	2114	particular
O	2115	2122	benefit
O	2123	2127	from
O	2128	2131	PRT
O	2132	2134	on
O	2135	2141	global
O	2142	2148	health
O	2149	2155	status
O	2156	2159	and
O	2160	2166	social
O	2167	2178	functioning
O	2178	2179	.
